A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2006
11/21/2006	US7138426 Estrogen receptor modulators
11/21/2006	US7138425 Phthalimide carboxylic acid derivatives
11/21/2006	US7138424 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
11/21/2006	US7138420 Substituted benzimidazole compounds
11/21/2006	US7138416 Compounds and therapeutic uses thereof
11/21/2006	US7138413 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders
11/21/2006	US7138411 Substituted benzopyran derivatives for the treatment of inflammation
11/21/2006	US7138410 Aza-bicyclic N-biarylamides with affinity for the α7 nicotinic acetylcholine receptor
11/21/2006	US7138409 Heterocyclic compounds
11/21/2006	US7138407 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
11/21/2006	US7138406 Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders
11/21/2006	US7138404 Anxiolytic agents and analgesics
11/21/2006	US7138400 N-substituted with a methylene-bridged nonaromatic ring system, e.g., N-(2-(benzyloxy)-5,6,7,8,9,10-hexahydro-6,9-methanobenzo(a)(8)annulen-11-yl)-N'-(2,2,2-trifluoroethyl)-sulfamide; preventing or treating Alzheimer's Disease
11/21/2006	US7138397 Nitrogenous 5-membered ring compounds
11/21/2006	US7138396 Treating androgen-dependent diseases, particularly benign prostatic hyperplasia, with a piperidinyl- or piperazinyl- N-(4-substituted pentamethylene)- or N-(4-substituted iminodiethylene)- acetamide derivative, optionally in combination with an alpha-1 adrenergic antagonist
11/21/2006	US7138383 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity
11/21/2006	US7138379 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
11/21/2006	US7138377 Substituted sugar derivatives of indolopyrrolocarbazoles, useful in inhibiting the proliferatin of tumor cells
11/21/2006	US7138371 Remodeling and glycoconjugation of peptides
11/21/2006	US7138243 NTB-A, a surface molecule involved in natural killer cells activity
11/21/2006	US7138236 Interactions of ATM, ATR or DAN-PK with p53
11/21/2006	US7138146 Acrochordon alleviation
11/21/2006	US7138134 Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
11/21/2006	US7138133 Orally administered liquid compositions
11/21/2006	US7138120 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
11/21/2006	US7138117 Antigen-binding fragment or antibody which binds to a mammalian CC-chemokine receptor 4 (CCR4); medical diagosis, therapy, or prophylaxis; antiinflammatory agents
11/21/2006	CA2327693C Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
11/21/2006	CA2318260C Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
11/21/2006	CA2302156C Methods for modulating the axonal outgrowth of central nervous system neurons
11/21/2006	CA2258971C Use of a cosmetic compound for the treatment and prevention of acne rosacea
11/21/2006	CA2247257C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
11/21/2006	CA2204478C Fluorinated vitamin d3 analogs
11/21/2006	CA2178105C Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
11/21/2006	CA2164061C Cosmetic compositions containing lactate dehydrogenase inhibitors
11/21/2006	CA2140441C Inhibitors of c-amp phosphodiesterase and tnf
11/21/2006	CA2120619C Novel potent inducers of terminal differentiation and methods of use thereof
11/16/2006	WO2006122154A2 Pyridone derivatives for modulating stress-activated protein kinase system
11/16/2006	WO2006121263A1 Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
11/16/2006	WO2006121219A1 Agent for controlling epithelial-mesenchymal transition
11/16/2006	WO2006121106A1 Method for producing indole derivative having piperidine ring
11/16/2006	WO2006121104A1 Crystal of indole derivative having piperidine ring and process for production thereof
11/16/2006	WO2006121097A1 Bicyclic heterocyclic derivative or salt thereof
11/16/2006	WO2006120360A2 Active composition for treatment or prevention of problems related to a disturbance of the biological clock
11/16/2006	WO2002094236A9 Delivery of antipsychotics through an inhalation route
11/16/2006	US20060258860 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; for preventing, treating or delaying AIDS
11/16/2006	US20060258731 Antitumor compound and therapeutic uses thereof
11/16/2006	US20060258726 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
11/16/2006	US20060258724 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents; Alzheimer's disease; anticancer agents
11/16/2006	US20060258707 Benzimidazolidinone derivatives as muscarinic agents
11/16/2006	US20060258702 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258701 glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus; 3-(4-methoxy-phenylsulfanyl)-6-(4H-[1,2,4]triazol-3-yl-sulfanyl)-N-([1,3,4]thiadiazol-2-yl)-2-pyridine carboxamide
11/16/2006	US20060258700 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
11/16/2006	US20060258678 Novel indole derivatives
11/16/2006	US20060258660 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258658 Triazole compounds useful as protein kinase inhibitors
11/16/2006	US20060258653 Derivatives of sulphonamides, their preparation and use as medicaments
11/16/2006	US20060258638 Succinoylamino lactams as inhibitors of A-beta protein production
11/16/2006	US20060258637 Fused polycyclic compounds
11/16/2006	US20060258602 Site-specific gene conversion promoter and gene therapeutic
11/16/2006	US20060258588 Compositions and methods for treating articular cartilage disorders
11/16/2006	US20060258563 Nitrogen Oxide scavenging ability; digesting cytochrome c with restriction enzyme; use in prophylactic and therapeutics, measuring/treating nitrogen oxide concentrations in air, exhaust gas or water
11/16/2006	US20060257989 Truncated aggrecanase molecules
11/16/2006	US20060257965 Extracellular matrix signalling molecules
11/16/2006	US20060257917 Fluorescent dyes, energy transfer couples and methods
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257843 Kappa-PVIIA-related conotoxins as organ protectants
11/16/2006	US20060257474 anti-thrombocytic agent and an HMG-CoA reductase inhibitor in an amount sufficient to treat chronic glomerular nephritis wherein the anti-thrombocytic agent is selected from dilazep, dipyridamole and or salts thereof and the HMG-CoA reductase inhibitor is pitavastatin
11/16/2006	US20060257366 Chimeric glycoproteins and pseudotyped lentiviral vectors
11/16/2006	US20060257351 administering, to a subject a formulation containing2-(3,4-dihydroxyphenyl)ethanol or a glucoside; and cysteine or cystine for potentiating glutathione, for promoting the production of a gamma -glutamylcysteine synthetase, glutathione reductase; antiaging agents, nutraceuticals, sunscreen agents
11/16/2006	US20060257329 Delivery of drug esters through an inhalation route
11/16/2006	DE102005023301A1 Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
11/16/2006	CA2608116A1 Method of modulating stress-activated protein kinase system
11/16/2006	CA2608060A1 Composition for treatment or prevention of problems relating to a disturbance of the biological clock
11/16/2006	CA2607639A1 Crystal of indole derivative having piperidine ring and process for production thereof
11/15/2006	EP1721905A1 Thiazole derivative
11/15/2006	EP1721904A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/15/2006	EP1721901A1 Abc transporter inhibitor
11/15/2006	EP1721610A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
11/15/2006	EP1721608A2 Upregulation of type III endothelial cell nitric oxide synthase by HMG-CoA reductase inhibitors
11/15/2006	EP1511482B1 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
11/15/2006	EP1474127B1 Biphenyl derivatives and their use as antiandrogenic agents
11/15/2006	EP1453511B1 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
11/15/2006	EP1450799B1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
11/15/2006	EP1423121B1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
11/15/2006	EP1416927B1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
11/15/2006	EP1414443B1 BENZIMIDAZO 4,5-f\|ISOQUINOLINONE DERIVATIVES
11/15/2006	EP1411881B9 5ht2c receptor modulators
11/15/2006	EP1406899B1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/15/2006	EP1401434B1 Modulators of peroxisome proliferator activated receptors (ppar)
11/15/2006	EP1392692B1 (oxo-pyrazolo¬1,5a\|pyrimidin-2-yl)alkyl-carboxamides
11/15/2006	EP1363648B1 Agastache rugosa extract having anti-inflammatory activity and anti-atherogenic activity
11/15/2006	EP1345942B9 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists
11/15/2006	EP1335919B1 Triazolo[4,5-d]pyrimidine derivatives as anti-thrombotic agents
11/15/2006	EP1326610B1 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
11/15/2006	EP1324991B1 Compounds useful in the treatment of inflammatory diseases
11/15/2006	EP1323711B1 Novel phenylalanine derivatives
11/15/2006	EP1152731B1 A skin care composition that mediates cell to cell communication
11/15/2006	EP1142885B1 2-(n-cyanoimino)thiazolidin-4-one derivatives
11/15/2006	EP1093363B1 Compositions for treatment of disorders associated with chlamydia

1 ... 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 ... 1564